Johnson & Johnson Presents Nucynta Tablets Phase 3 Study Results
The data are expected to be presented during a poster session at the 29th Annual Scientific Meeting of the American Pain Society (APS), and are supported by PriCara,
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.